Skip to main content
  • English
  • Català
  • Español
Home
  • Company
    • Overview & History
    • Team
    • Join Oryzon
  • Epigenetics
    • Histone Code Hypothesis
    • Modulator Enzymes
    • LSD1 & Disease
    • Technology Platforms
    • Scientific Publications by Oryzon
  • Therapeutic Programs
    • Strategy
    • LSD1 & Cancer
    • Oryzon's Pipeline
  • Collaborative Research
    • Collaborative Projects
  • For Patient
    • Patient Information
  • Shareholders and Investors
    • Investor Information and News
    • Share Information
    • Events & Presentations
    • Financial Information & Downloads
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Press Releases
  • Contact
    • General Contact
    • Investor Contact
    • Email Alerts

News

Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

News & Press Releases

29 December 2015
Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors
16 December 2015
ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease
10 December 2015
Oryzon Genomics Announces Listing on Madrid Stock Exchange
30 November 2015
ORYZON to Present at the Neuroscience R&D Technologies Conference
10 November 2015
Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001
4 November 2015
ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors
27 October 2015
ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs
16 September 2015
ORYZON shareholders approve listing to the Spanish Continuous Market
7 September 2015
ORYZON achieves milestone in the clinical development of ORY-1001
31 August 2015
ORYZON to Present at The Epigenetics Discovery Congress in London

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

epigen-logo

Epigenetic drugs for a better world.

United States

Oryzon Corporate
245 First Street, Suite 1800
Cambridge, MA 02142

T: (617) 444-8786
F: (617) 444- 8405
info@oryzon.com

Spain

Oryzon Genomics
Sant Ferran 74
08940 Cornellà de Llobregat, Barcelona, Spain

T: (+34) 93 515 1313
F: (+34) 93 377 4028
info@oryzon.com

Legal Advice
Privacy Policy

Investor Information

ISIN: ES0167733015 - ORY

Please contact us for investor information.

Contact Us

© 2019

Oryzon Genomics

All Rights Reserved

  • Legal Advice
  • Privacy Policy
  • Registered address: Carrera de San Jerónimo 15, 2ª planta, 28014 Madrid (Spain)